지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 495 - 505 (11page)
이용수
초록· 키워드
오류제보하기
Purpose In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT) protein expression were studied to investigate potential correlations between these molecular characteristics and clinical features or outcomes in neuroblastoma. Materials and Methods Seventy-two patients were enrolled in this study. Polymerase chain reaction amplification and direct sequencing were used for mutation analysis. ALK and MYCN amplifications were detected by fluorescence in situ hybridization. Protein expression was evaluated by immunohistochemical (IHC) staining. Results ALK mutation was found in only two patients (4.1%); ALK amplification was not detected. ALK positivity, loss of nuclear ATRX protein, TERT positivity by IHC were detected in 40 (55.6%), nine (13.0%), and 42 (59.2%) patients, respectively. The incidence of ALK expression increased in accordance with increasing tumor stage (p=0.001) and risk group (p < 0.001). The relapse rate was significantly higher in ALK+ patients compared to that of other patients (47.5% vs. 11.3%, p=0.007). However, there was no significant difference in relapse rate when the survival analysis was confined to the high-risk patients. Conclusion Although ALKmutation was rare and no amplification was observed, ALK protein expression was found in a significant number of patients and was correlated with advanced stage and high-risk neuroblastoma. ALK protein expression could be considered as a marker related to the aggressive neuroblastoma, but it was not the independent prognostic factor for the outcome.
목차
등록된 정보가 없습니다.
참고문헌 (30)
참고문헌 신청
Maris JM / 2007 / Neuroblastoma / Lancet 369:2106~2120
Ambros PF / 2009 / International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee / Br J Cancer 100:1471~1482
Janoueix-Lerosey I / 2009 / Overall genomic pattern is a predictor of outcome in neuroblastoma / J Clin Oncol 27:1026~1033
Ladenstein R / 2001 / Prognostic significance of DNA di-tetraploidy in neuroblastoma / Med Pediatr Oncol 36:83~92
Stallings RL / 2007 / Are chromosomal imbalances important in cancer? / Trends Genet 23:278~283
Ambros PF / 2009 / International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee / Br J Cancer 100:1471~1482
Janoueix-Lerosey I / 2009 / Overall genomic pattern is a predictor of outcome in neuroblastoma / J Clin Oncol 27:1026~1033
Ladenstein R / 2001 / Prognostic significance of DNA di-tetraploidy in neuroblastoma / Med Pediatr Oncol 36:83~92
Stallings RL / 2007 / Are chromosomal imbalances important in cancer? / Trends Genet 23:278~283
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features
Journal of Pathology and Translational Medicine
2024 .01
-
Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations
Journal of Pathology and Translational Medicine
2021 .01
-
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
Cancer Research and Treatment
2019 .01
-
Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
Journal of Pathology and Translational Medicine
2015 .01
-
A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation
Cancer Research and Treatment
2021 .01
-
Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
Yonsei Medical Journal
2020 .01
-
Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center
Journal of Pathology and Translational Medicine
2017 .01
-
Prognostic and predictive markers in glioblastoma and ALK overexpression
Journal of Pathology and Translational Medicine
2021 .01
-
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Yonsei Medical Journal
2018 .01
-
SEC31A-ALKFusion Gene in Lung Adenocarcinoma
Cancer Research and Treatment
2016 .01
-
A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
Journal of Pathology and Translational Medicine
2021 .01
-
Treatment of High-Risk Neuroblastoma
대한외과학회 학술대회 초록집
2019 .10
-
EGFR 돌연변이와 ALK 재배열 공존하는 폐선암 환자 1예
대한내과학회지
2016 .01
-
Recent Topics in Fibrodysplasia Ossificans Progressiva
Endocrinology and Metabolism
2018 .01
-
Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma
Cancer Research and Treatment
2016 .01
-
ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
Blood Research
2022 .03
-
Oral spindle cell/sclerosing rhabdomyosarcoma on mandible with anaplastic lymphoma kinase expression mimicking inflammatory myofibroblastic tumor
대한구강악안면외과학회지
2023 .04
-
Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
Cancer Research and Treatment
2023 .01
-
The New Era: Surgical Management of Neuroblastoma
대한외과학회 학술대회 초록집
2019 .10
-
A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0